🇺🇸 ALECTINIB in United States

1,197 US adverse-event reports

Marketing authorisation

FDA

  • Status: approved

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Disease Progression — 182 reports (15.2%)
  2. Anaemia — 166 reports (13.87%)
  3. Fatigue — 136 reports (11.36%)
  4. Drug Ineffective — 125 reports (10.44%)
  5. Constipation — 113 reports (9.44%)
  6. Blood Bilirubin Increased — 103 reports (8.6%)
  7. Metastases To Central Nervous System — 100 reports (8.35%)
  8. Aspartate Aminotransferase Increased — 98 reports (8.19%)
  9. Nausea — 87 reports (7.27%)
  10. Neoplasm Progression — 87 reports (7.27%)

Source database →

ALECTINIB in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Frequently asked questions

Is ALECTINIB approved in United States?

Yes. FDA has authorised it.

Who is the marketing authorisation holder for ALECTINIB in United States?

Marketing authorisation holder not available in our data.